BALPX
Price
$10.00
Change
+$0.02 (+0.20%)
Updated
Aug 21 closing price
Net Assets
4.82B
CMRAX
Price
$10.65
Change
-$0.00 (-0.00%)
Updated
Aug 21 closing price
Net Assets
2.63M
Interact to see
Advertisement

BALPX vs CMRAX

BALPX vs CMRAX Comparison Chart in %
View a ticker or compare two or three
VS
BALPX vs. CMRAX commentary
Aug 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BALPX is a Hold and CMRAX is a Buy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
BALPX has more cash in the bank: 4.82B vs. CMRAX (2.63M). CMRAX pays higher dividends than BALPX: CMRAX (1.07) vs BALPX (0.67). BALPX was incepted earlier than CMRAX: BALPX (19 years) vs CMRAX (3 years). CMRAX (6.59) is less costly to investors than BALPX (1.60). CMRAX is a more actively managed with annual turnover of: 177.00 vs. BALPX (81.00). BALPX initial investment is less costly to investors than CMRAX (3%) vs CMRAX (3%). BALPX has a lower initial minimum investment than CMRAX: BALPX (1000) vs CMRAX (2500). BALPX annual gain was more profitable for investors over the last year : 2.53 vs. CMRAX (2.06).
BALPXCMRAXBALPX / CMRAX
Total Expense Ratio1.511.9876%
Annual Report Gross Expense Ratio1.606.5924%
Fund Existence19 years3 years-
Gain YTD1.3175.13326%
Front Load5%3%191%
Min. Initial Investment1000250040%
Min. Initial Investment IRAN/AN/A-
Net Assets4.82B2.63M183,055%
Annual Yield % from dividends0.671.0763%
Returns for 1 year2.532.06123%
Returns for 3 years15.41N/A-
Returns for 5 years15.26N/A-
Returns for 10 years30.43-60.11-51%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RTIRX14.890.14
+0.95%
Russell Inv Multifactor Intl Eq R6
SUIRX78.340.50
+0.64%
DWS CROCI International R6
ISMVX13.860.07
+0.51%
William Blair Small-Mid Cap Value I
OPTFX90.650.25
+0.28%
Invesco Discovery Large Cap A
DWOCX14.12N/A
N/A
BNY Mellon Research Growth C